Gyre Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Gyre Therapeutics, Inc. (GYRE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 84.30% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2025-03-17
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-06-30 was 67.35%, a 0.97% increase year-over-year.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2014-06-30 was 66.70%.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 84.30%, a 0.00% change from fiscal 2023.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 84.30%.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2014 was 111.00%, a 35.37% increase from fiscal 2013.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2013 was 82.00%, a 18.84% increase from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|
| 2024-12-31 | 84.30% 10-K · filed 2025-03-17 | ||
| 2023-12-31 | 84.30% 10-K · filed 2024-03-27 | ||
| 2015-06-30 | 67.35% 8-K/A · filed 2015-10-23 | 67.19% 8-K/A · filed 2015-10-23 | |
| 2014-12-31 | 111.00% 10-K · filed 2015-03-16 | ||
| 2014-06-30 | 66.70% 8-K/A · filed 2015-10-23 | 64.62% 8-K/A · filed 2015-10-23 | |
| 2013-12-31 | 82.00% 10-K · filed 2015-03-16 | ||
| 2012-12-31 | 69.00% 10-K · filed 2015-03-16 | ||
| 2011-12-31 | 67.00% 10-K · filed 2014-03-14 | ||
| 2010-12-31 | 75.00% 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |